The Centre for the Studies of Asphyxia and Resuscitation

CSAR recognizes the importance of being involved in drug trials to identify the safest and most efficient treatment for preterm and term infants.

CSAR has ample experience with drug trials and all the necessary regulatory requirements.

​

 

Pharmaceutical Studies CSAR is currently involved:

• OPTIMIST A

• PLUS+S

• NANO-Trial

• Evaluation of the Clinical Efficacy and Safety of SHP607​

 

 

Pharmaceutical Studies CSAR has been involved:

• HIP-Trial

• Curosurf vs. BLES

• Lucinactant For Inhalation In Preterm Neonates (26-28 weeks)

• Lucinactant For Inhalation In Preterm Neonates (26-32 weeks)

 

 

If you want to talk to CSAR about conduction a drug trial, please email us at georg.schmoelzer@me.com.